We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Other Targets

Other Targets lists biosimilar antibodies whose targets fall outside the main groups or have few products. Examples include omalizumab and ligelizumab, which bind immunoglobulin E (IgE), and bimagrumab, which blocks activin type II receptors. Lirilumab targets killer-cell immunoglobulin-like receptors (KIRs) on natural killer cells. The group also includes antibodies to allergens, Wnt pathway receptors, proteases, transporters and intracellular proteins such as histones. Several fusion proteins and peptide conjugates are listed here as well, including the long-acting granulocyte colony-stimulating factor (G-CSF) analogs balugrastim and eflapegrastim.

3 Items

  • Mapatumumab — antibody illustration
    Cat. No.
    AT0113
    CAS No.
    658052-09-6

    Mapatumumab

    Synonyms: HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody

    Mapatumumab (HGS-ETR1) is a fully human IgG1 monoclonal antibody designed as an agonist for tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). This antibody selectively binds to TRAIL-R1, potentially inducing apoptosis in cells expressing this receptor. Mapatumumab is primarily utilized in oncological research to study its efficacy and mechanism in promoting cancer cell apoptosis.

    In stock View Details
    1 mg
    $240.00
    5 mg
    $720.00
    All 3 sizes
  • Neihulizumab — antibody illustration
    Cat. No.
    AT0484
    CAS No.
    2158362-38-8

    Neihulizumab

    Synonyms: ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab

    Neihulizumab (ALTB-168) functions as an agonistic antibody targeting the immune checkpoint receptor CD162, also known as PSGL-1. By binding to this receptor, Neihulizumab effectively mediates the downregulation of activated T-cells. This antibody is primarily utilized in research focusing on steroid-refractory acute graft-versus-host disease (SR-aGVHD), as well as studies related to psoriasis, psoriatic arthritis, and ulcerative colitis. Its unique mechanism and specificity make it a valuable tool in the investigation of immune response modulation in these conditions.

    In stock View Details
    1 mg
    $360.00
    5 mg
    $1,008.00
    All 3 sizes
  • Iluzanebart — antibody illustration
    Cat. No.
    AT1244
    CAS No.
    2733621-19-5

    Iluzanebart

    Iluzanebart is a human monoclonal IgG1 antibody designed as an agonist for human Triggering Receptor Expressed on Myeloid cells 2 (hTREM2). This antibody enhances the survival and functionality of microglia by activating the TREM2 signaling pathway, thereby compensating for deficits in CSF1R (Colony Stimulating Factor 1 Receptor) function. It is specifically developed for use in research related to adult-onset leukoencephalopathy with CSF1R pathology (CSF1R-ALSP), providing a valuable tool for investigating the molecular mechanisms and potential therapeutic targets for this condition.

    In stock View Details
    1 mg
    $240.00
    5 mg
    $600.00
    All 3 sizes

3 Items

Added to your cart

View Cart Checkout

    Loading...